<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-12-03" updated="2019-12-02">
  <drugbank-id primary="true">DB11160</drugbank-id>
  <name>Phenyltoloxamine</name>
  <description>Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. Phenyltoloxamine citrate is the more common salt form that acts as an active ingredient in pharmaceutical products and promotes hay fever relief via reversing the effects of histamine. Phenyltoloxamine acts as an adjuvant analgesic, which augments the analgesic effect of acetaminophen. It also potentiates the effects of other drugs, such as codeine and codeine derivatives.&#13;
&#13;
Although phenyltoloxamine's ability to potentiate the effects of analgesics may be explained in part by its chemical nature as a first-generation H1 antihistamine that is capable of crossing the blood-brain barrier and causing tranquilizing effects at CNS histamine receptors, many of the drug's specific pharmacokinetics are not readily available - perhaps also because many early (phenyltoloxamine was involved in studies as early as the 1950s) first-generation antihistamines were not optimally investigated [A32705]. Nevertheless, phenyltoloxamine is used to a fairly limited extent in contemporary medicine, with only very few products involving it as an active ingredient.</description>
  <cas-number>92-12-6</cas-number>
  <unii>K65LB6598J</unii>
  <average-mass>255.361</average-mass>
  <monoisotopic-mass>255.1623143</monoisotopic-mass>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32705</ref-id>
        <pubmed-id>23282578</pubmed-id>
        <citation>Simons FE, Simons KJ: H1 antihistamines: current status and future directions. World Allergy Organ J. 2008 Sep;1(9):145-55. doi: 10.1097/WOX.0b013e318186fb3a.</citation>
      </article>
      <article>
        <ref-id>A32707</ref-id>
        <pubmed-id>5492933</pubmed-id>
        <citation>Dotti A: [Clinical trial of the antitussive action of an association of codeine plus phenyltoloxamine]. G Ital Mal Torace. 1970 May-Jun;24(3):147-57.</citation>
      </article>
      <article>
        <ref-id>A32708</ref-id>
        <pubmed-id>2569485</pubmed-id>
        <citation>Sunshine A, Zighelboim I, De Castro A, Sorrentino JV, Smith DS, Bartizek RD, Olson NZ: Augmentation of acetaminophen analgesia by the antihistamine phenyltoloxamine. J Clin Pharmacol. 1989 Jul;29(7):660-4.</citation>
      </article>
      <article>
        <ref-id>A32709</ref-id>
        <pubmed-id>821705</pubmed-id>
        <citation>Gilbert MM, De Sola Pool N, Schecter C: Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Curr Ther Res Clin Exp. 1976 Jul;20(1):53-8.</citation>
      </article>
      <article>
        <ref-id>A32710</ref-id>
        <pubmed-id>23282332</pubmed-id>
        <citation>Church DS, Church MK: Pharmacology of antihistamines. World Allergy Organ J. 2011 Mar;4(3 Suppl):S22-7. doi: 10.1097/WOX.0b013e3181f385d9.</citation>
      </article>
      <article>
        <ref-id>A32712</ref-id>
        <pubmed-id>6483639</pubmed-id>
        <citation>Forbes JA, Barkaszi BA, Ragland RN, Hankle JJ: Analgesic effect of acetaminophen, phenyltoloxamine and their combination in postoperative oral surgery pain. Pharmacotherapy. 1984 Jul-Aug;4(4):221-6.</citation>
      </article>
      <article>
        <ref-id>A32713</ref-id>
        <pubmed-id>13096396</pubmed-id>
        <citation>HOEKSTRA JB, TISCH DE, RAKIETEN N, DICKISON HL: Pharmacological properties of a new antihistaminic agent, phenyltoloxamine (Bristamin). J Am Pharm Assoc Am Pharm Assoc. 1953 Oct;42(10):587-93.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L2495</ref-id>
        <title>Prescribing Information: Tussionex Suspension and Tablets</title>
        <url>http://products.sanofi.ca/en/tussionex.pdf</url>
      </link>
      <link>
        <ref-id>L2499</ref-id>
        <title>DailyMed: Dologesic( acetaminophen, phenyltoloxamine citrate, alcool liquid)</title>
        <url>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=738e7767-42de-4076-acf2-9152484c2007</url>
      </link>
      <link>
        <ref-id>L2508</ref-id>
        <title>SMPDB: Phenyltoloxamine H1-Antihistamine Action</title>
        <url>http://smpdb.ca/view/SMP58916</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>The primary therapeutic use for which phenyltoloxamine is currently indicated is as an adjuvant therapy in various combination products containing an analgesic(s) (either narcotic or non-narcotic), where it is expected to potentiate the pain relieving, anti-tussive, etc. effect(s) of the analgesic component of the product.&#13;
&#13;
In that regard, some of these aforementioned combination products are typically indicated for the temporary relief of minor aches and pains like headache, muscular aches, backaches, minor arthritis pain, common cold, toothaches, menstrual cramps, etc [L2499]; or perhaps for the treatment of exhausting or non-productive cough, associated with cold or with upper respiratory allergic condition that does not respond to non-narcotic antitussives [L2495].</indication>
  <pharmacodynamics>As a member of the first generation H1 antihistamines, it is known that phenyltoloxamine - like virtually all first generation H1 antihistamines - has a propensity for crossing the blood-brain barrier and acting on H1 histamine receptors there to interfere with neurotransmission [A32705]. The most common results of this kind of first generation H1 antihistamine CNS neurotransmission interference are adverse effects like drowsiness, sedation, somnolence, and fatigue [A32705]. Given these effects, under specific circumstances like a patient experiencing a pain or a cough that may be preoccupying all of their waking energy and attention, it is perhaps possible that the sedative and tranquilizing characteristics of phenyltoloxamine may be the factors that contribute to its apparent adjunctive analgesic [A32708, A32709] and antitussive actions [L2495, A32707]. </pharmacodynamics>
  <mechanism-of-action>As a first-generation H1 antihistamine, phenyltoloxamine interferes with the agonist activity of histamine at the H1 receptor and are ostensibly used to attenuate inflammatory processes as a means to treat conditions like allergic rhinitis, allergic conjunctivitis, and urticaria [L2508]. Reduction of the activity of the NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) immune response transcription factor via the phospholipase C and phosphatidylinositol (PIP2) signaling pathways also serves to decrease antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors [L2508]. Moreover, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release [L2508].&#13;
&#13;
Additionally, first-generation antihistamines like phenyltoloxamine readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects, like nervousness and insomnia [L2508]. By comparison, second-generation antihistamines are more selective for H1 receptors in the peripheral nervous system and do not cross the blood-brain barrier, resulting in fewer adverse drug effects overall [L2508].&#13;
&#13;
Furthermore, although some studies propose that phenyltoloxamine may possess some intrinsic antispasmodic and distinct local anesthetic properties [A32713], the specific mechanisms of action for these effects have not been formalized. Also, even though the combination of phenyltoloxamine's ability to cross the blood-brain barrier and cause various tranquilizing effects may explain to some extent how it may be able to potentiate analgesic effects [A32708, A32709], there are also studies that observed no potentiating effects associated with phenyltoloxamine use either [A32712].</mechanism-of-action>
  <toxicity>Toxicity after overdose may involve CNS effects like extreme drowsiness, lethargy, confusion, delirium, and coma in adults; paradoxical excitation, irritability, hyperactivity, insomnia, hallucinations, seizures, and respiratory depression or arrest in infants and young children, CNS adverse effects predominate o er cardiac adverse effects; death may occur within hours after ingestion of drug in untreated patients; rhabdomyolysis has also been reported [A32705].</toxicity>
  <metabolism>Readily accessible data regarding the metabolism of phenyltoloxamine is not available. In fact, many first-generation H1 antihistamines have never had their pharmacokinetics (ie. absorption, distribution, metabolism, and elimination) optimally investigated [A32705].</metabolism>
  <absorption>Readily accessible data regarding the absorption of phenyltoloxamine is not available. In fact, many first-generation H1 antihistamines have never had their pharmacokinetics (ie. absorption, distribution, metabolism, and elimination) optimally investigated [A32705].</absorption>
  <half-life>Readily accessible data regarding the half-life of phenyltoloxamine is not available. In fact, many first-generation H1 antihistamines have never had their pharmacokinetics (ie. absorption, distribution, metabolism, and elimination) optimally investigated [A32705].</half-life>
  <protein-binding>Readily accessible data regarding the protein binding of phenyltoloxamine is not available. In fact, many first-generation H1 antihistamines have never had their pharmacokinetics (ie. absorption, distribution, metabolism, and elimination) optimally investigated [A32705].</protein-binding>
  <route-of-elimination>Readily accessible data regarding the primary route of elimination of phenyltoloxamine is not available. In fact, many first-generation H1 antihistamines have never had their pharmacokinetics (ie. absorption, distribution, metabolism, and elimination) optimally investigated [A32705].</route-of-elimination>
  <volume-of-distribution>Readily accessible data regarding the volume of distribution of phenyltoloxamine is not available. In fact, many first-generation H1 antihistamines have never had their pharmacokinetics (ie. absorption, distribution, metabolism, and elimination) optimally investigated [A32705].</volume-of-distribution>
  <clearance>Readily accessible data regarding the clearance of phenyltoloxamine is not available. In fact, many first-generation H1 antihistamines have never had their pharmacokinetics (ie. absorption, distribution, metabolism, and elimination) optimally investigated [A32705].</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.</description>
    <direct-parent>Diphenylmethanes</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Diphenylmethanes</subclass>
    <alternative-parent>Alkyl aryl ethers</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Phenol ethers</alternative-parent>
    <alternative-parent>Phenoxy compounds</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <substituent>Alkyl aryl ether</substituent>
    <substituent>Amine</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>Diphenylmethane</substituent>
    <substituent>Ether</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenol ether</substituent>
    <substituent>Phenoxy compound</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001531</drugbank-id>
      <name>Phenyltoloxamine citrate</name>
      <unii>8UE48MJH8M</unii>
      <cas-number>1176-08-5</cas-number>
      <inchikey>ZZYHCCDMBJTROG-UHFFFAOYSA-N</inchikey>
      <average-mass>447.484</average-mass>
      <monoisotopic-mass>447.189316898</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT002682</drugbank-id>
      <name>Phenyltoloxamine hydrochloride</name>
      <unii>56O4H6ZT2K</unii>
      <cas-number>6152-43-8</cas-number>
      <inchikey>HMBOWANDONYIBI-UHFFFAOYSA-N</inchikey>
      <average-mass>291.82</average-mass>
      <monoisotopic-mass>291.138992</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="spanish" coder="">Feniltoloxamina</synonym>
    <synonym language="english" coder="inn">Phenyltoloxamine</synonym>
    <synonym language="latin" coder="">Phenyltoloxaminum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Ali-flex</name>
      <labeller>Pegasus Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55246-816</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-06-27</started-marketing-on>
      <ended-marketing-on>2012-07-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Be Flex Plus</name>
      <labeller>Larken Laboratories, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68047-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-17</started-marketing-on>
      <ended-marketing-on>2010-07-13</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Be Flex Plus</name>
      <labeller>Larken Laboratories, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68047-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-17</started-marketing-on>
      <ended-marketing-on>2010-07-13</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>BE-FLEX Plus</name>
      <labeller>Larken Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68047-116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-17</started-marketing-on>
      <ended-marketing-on>2011-10-31</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dologesic</name>
      <labeller>Llorens Pharmaceuticals International Division</labeller>
      <ndc-id/>
      <ndc-product-code>54859-512</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dologesic DF</name>
      <labeller>Llorens Pharmaceuticals International Division</labeller>
      <ndc-id/>
      <ndc-product-code>54859-110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Flextra-650</name>
      <labeller>Pegasus Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55246-650</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-08</started-marketing-on>
      <ended-marketing-on>2011-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Flextra-650</name>
      <labeller>Poly Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50991-650</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-08</started-marketing-on>
      <ended-marketing-on>2011-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norel SR</name>
      <labeller>Us Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>52747-420</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-01</started-marketing-on>
      <ended-marketing-on>2013-03-31</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Relagesic</name>
      <labeller>International Ethical Labs.</labeller>
      <ndc-id/>
      <ndc-product-code>11584-4770</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-15</started-marketing-on>
      <ended-marketing-on>2016-05-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Relagesic</name>
      <labeller>International Ethical Labs.</labeller>
      <ndc-id/>
      <ndc-product-code>11584-0476</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-16</started-marketing-on>
      <ended-marketing-on>2014-01-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rhinoflex-650</name>
      <labeller>Carwin Associates, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>15370-650</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-01-31</started-marketing-on>
      <ended-marketing-on>2013-11-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sinutab Sa Tab</name>
      <labeller>Warner Lambert Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01938398</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>2000-11-09</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Trital SR</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-529</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-01</started-marketing-on>
      <ended-marketing-on>2011-05-31</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tussionex</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01916971</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1957-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tussionex</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01916963</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1957-12-31</started-marketing-on>
      <ended-marketing-on>2017-08-24</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Zegesic</name>
      <labeller>Capellon Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>64543-400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-01</started-marketing-on>
      <ended-marketing-on>2013-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zflex</name>
      <labeller>Huckaby Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>35501-023</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Flextra-650</name>
      <ingredients>Acetaminophen + Phenyltoloxamine</ingredients>
    </mixture>
    <mixture>
      <name>Zflex</name>
      <ingredients>Acetaminophen + Phenyltoloxamine</ingredients>
    </mixture>
    <mixture>
      <name>Ali-flex</name>
      <ingredients>Acetaminophen + Phenyltoloxamine</ingredients>
    </mixture>
    <mixture>
      <name>Flextra-650</name>
      <ingredients>Acetaminophen + Phenyltoloxamine</ingredients>
    </mixture>
    <mixture>
      <name>Trital SR</name>
      <ingredients>Acetaminophen + Chlorpheniramine + Phenylephrine + Phenyltoloxamine</ingredients>
    </mixture>
    <mixture>
      <name>Dologesic DF</name>
      <ingredients>Acetaminophen + Phenyltoloxamine</ingredients>
    </mixture>
    <mixture>
      <name>Be Flex Plus</name>
      <ingredients>Acetaminophen + Phenyltoloxamine + Salicylamide</ingredients>
    </mixture>
    <mixture>
      <name>Be Flex Plus</name>
      <ingredients>Acetaminophen + Phenyltoloxamine + Salicylamide</ingredients>
    </mixture>
    <mixture>
      <name>Dologesic</name>
      <ingredients>Acetaminophen + Ethanol + Phenyltoloxamine</ingredients>
    </mixture>
    <mixture>
      <name>Norel SR</name>
      <ingredients>Acetaminophen + Chlorpheniramine + Phenylephrine + Phenyltoloxamine</ingredients>
    </mixture>
    <mixture>
      <name>Zegesic</name>
      <ingredients>Acetaminophen + Phenyltoloxamine</ingredients>
    </mixture>
    <mixture>
      <name>BE-FLEX Plus</name>
      <ingredients>Acetaminophen + Phenyltoloxamine + Salicylamide</ingredients>
    </mixture>
    <mixture>
      <name>Rhinoflex-650</name>
      <ingredients>Acetaminophen + Phenyltoloxamine</ingredients>
    </mixture>
    <mixture>
      <name>Relagesic</name>
      <ingredients>Acetaminophen + Phenyltoloxamine</ingredients>
    </mixture>
    <mixture>
      <name>Relagesic</name>
      <ingredients>Acetaminophen + Phenyltoloxamine</ingredients>
    </mixture>
    <mixture>
      <name>Tussionex</name>
      <ingredients>Hydrocodone + Phenyltoloxamine</ingredients>
    </mixture>
    <mixture>
      <name>Sinutab Sa Tab</name>
      <ingredients>Acetaminophen + Phenylpropanolamine + Phenyltoloxamine</ingredients>
    </mixture>
    <mixture>
      <name>Tussionex</name>
      <ingredients>Hydrocodone + Phenyltoloxamine</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Benzene Derivatives</category>
      <mesh-id>D001555</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule, gelatin coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.51</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.8</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>4.23e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.93</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>[2-(2-benzylphenoxy)ethyl]dimethylamine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>phenyltoloxamine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>255.361</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>255.1623143</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CN(C)CCOC1=CC=CC=C1CC1=CC=CC=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C17H21NO</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C17H21NO/c1-18(2)12-13-19-17-11-7-6-10-16(17)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>IZRPKIZLIFYYKR-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>12.47</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>80.28</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>29.99</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>8.78</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>6044</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>9946</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>135047</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>7077</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347827928</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>6810</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50151046</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Phenyltoloxamine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL186720</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways>
    <pathway>
      <smpdb-id>SMP0058916</smpdb-id>
      <name>Phenyltoloxamine H1-Antihistamine Action</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
        <drug>
          <drugbank-id>DB11160</drugbank-id>
          <name>Phenyltoloxamine</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>Q9NQ66</uniprot-id>
        <uniprot-id>P62873</uniprot-id>
        <uniprot-id>P59768</uniprot-id>
        <uniprot-id>P35367</uniprot-id>
        <uniprot-id>P50148</uniprot-id>
        <uniprot-id>Q14643</uniprot-id>
        <uniprot-id>P05771</uniprot-id>
        <uniprot-id>P19838</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0009144</id>
      <name>Histamine H1 receptor</name>
      <organism>Mouse</organism>
      <actions>
        <action>inverse agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A32705</ref-id>
            <pubmed-id>23282578</pubmed-id>
            <citation>Simons FE, Simons KJ: H1 antihistamines: current status and future directions. World Allergy Organ J. 2008 Sep;1(9):145-55. doi: 10.1097/WOX.0b013e318186fb3a.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P70174" source="Swiss-Prot">
        <name>Histamine H1 receptor</name>
        <general-function>In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system. Involved in circadian rhythm of locomotor activity and exploratory behavior. Also involved in responsiveness to pertussis toxin through its control of susceptibility to histamine hypersensitivity and enhancement of antigen-specific delayed-type hypersensitivity responses.</general-function>
        <specific-function>Calcium ion transmembrane transporter activity</specific-function>
        <gene-name>Hrh1</gene-name>
        <locus>6 53.05 cM</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>30-52
63-83
102-123
144-164
190-210
418-439
452-471</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>55681.225</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="10090">Mouse</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P70174</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>HRH1_MOUSE</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Bphs</synonym>
          <synonym>H1R</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051318|Histamine H1 receptor
MSLPNTSSASEDKMCEGNRTAMASPQLLPLVVVLSSISLVTVGLNLLVLYAVRSERKLHT
VGNLYIVSLSVADLIVGAVVMPMNILYLIMTKWSLGRPLCLFWLSMDYVASTASIFSVFI
LCIDRYRSVQQPLRYLRYRTKTRASATILGAWFLSFLWVIPILGWHHFTPLAPELREDKC
ETDFYNVTWFKIMTAIINFYLPTLLMLWFYVKIYKAVRRHCQHRQLTNGSLPTFLEIKLR
SEDAKEGAKKPGKESPWGVQKRPSRDPTGGLDQKSTSEDPKVTSPTVFSQEGERETVTRP
CFRLDVMQTQPVPEGDARGSKANDQTLSQPKMDEQSLSTCRRISETSEDQTLVDRQSFSR
TTDSDTSIEPGLGKVKARSRSNSGLDYIKVTWKRLRSHSRQYVSGLHLNRERKAAKQLGC
IMAAFILCWIPYFIFFMVIAFCNSCCSEPVHMFTIWLGYINSTLNPLIYPLCNENFKKTF
KKILHIRS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051319|Histamine H1 receptor (Hrh1)
ATGAGCCTTCCCAACACCTCTTCTGCCTCCGAAGACAAGATGTGTGAGGGGAACAGGACA
GCCATGGCCAGCCCTCAGCTGCTGCCCCTGGTGGTGGTTCTAAGTAGTATCTCCCTGGTC
ACAGTGGGCCTCAACCTGCTGGTGCTGTATGCAGTGCGCAGTGAGCGCAAGCTACACACC
GTGGGCAACCTGTACATTGTCAGCCTGTCGGTAGCAGACCTGATTGTAGGGGCAGTCGTC
ATGCCCATGAACATCCTCTATCTTATCATGACCAAGTGGTCCCTGGGCCGCCCCCTCTGC
CTCTTTTGGCTCTCTATGGATTATGTGGCCAGCACGGCATCCATCTTTAGTGTCTTCATC
CTGTGTATTGATCGCTACCGCTCTGTCCAGCAACCCCTCCGGTACCTGAGGTATCGAACC
AAGACCCGTGCTTCAGCTACCATCCTGGGGGCCTGGTTTCTCTCCTTCCTGTGGGTTATA
CCTATACTTGGCTGGCATCACTTCACGCCCCTGGCCCCAGAGCTTCGGGAAGATAAGTGT
GAGACAGATTTCTACAATGTCACTTGGTTCAAGATCATGACCGCCATCATCAACTTCTAC
CTCCCCACTTTGCTCATGCTGTGGTTCTATGTGAAGATCTACAAGGCTGTGCGGCGACAC
TGTCAGCACCGCCAGCTCACCAACGGGTCCCTCCCTACCTTTTTAGAAATCAAGCTGAGG
TCGGAGGATGCCAAAGAGGGTGCCAAGAAACCTGGGAAAGAGTCTCCCTGGGGGGTCCAG
AAGAGGCCGTCAAGAGACCCTACTGGAGGTCTGGATCAGAAGTCAACATCTGAAGACCCC
AAGGTGACCTCTCCGACTGTCTTCAGCCAAGAGGGGGAAAGGGAAACAGTCACACGCCCC
TGTTTCCGTCTTGACGTCATGCAGACACAGCCTGTGCCTGAGGGAGATGCCAGGGGCTCA
AAGGCCAATGACCAGACCTTGAGCCAGCCCAAAATGGATGAGCAGAGCCTGAGTACTTGC
CGGCGGATCAGTGAGACATCAGAGGACCAGACCTTGGTGGATCGACAGTCCTTCTCCCGG
ACCACAGACTCAGACACCAGCATAGAGCCAGGGCTGGGCAAAGTCAAAGCGAGAAGCAGG
TCTAACAGTGGCCTGGACTACATCAAAGTCACCTGGAAGAGGCTCCGCTCACATTCCAGA
CAGTATGTGTCCGGGTTGCACTTGAACCGAGAGCGGAAGGCAGCCAAGCAGTTGGGTTGT
ATCATGGCAGCATTCATTCTCTGCTGGATTCCCTATTTCATCTTCTTCATGGTCATTGCC
TTCTGCAACAGCTGCTGCAGCGAACCTGTGCACATGTTCACCATTTGGCTGGGCTACATC
AACTCCACGCTGAACCCCCTCATCTACCCGCTGTGCAACGAGAACTTCAAGAAGACATTC
AAAAAAATTCTGCACATTCGTTCCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>histamine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to histamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>eosinophil chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>manganese ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of synaptic plasticity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vascular permeability</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>rhythmic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>